Tag: US10170A1007

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsUS10170A1007

PUDO Inc announces earnings call for Q1 FY 2026 – save the date

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe

Tag: US10170A1007

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us